Cargando…
Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma sa...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/ https://www.ncbi.nlm.nih.gov/pubmed/25256831 http://dx.doi.org/10.3390/cancers6031753 |
_version_ | 1782338538544562176 |
---|---|
author | Martinetti, Antonia Miceli, Rosalba Sottotetti, Elisa Di Bartolomeo, Maria de Braud, Filippo Gevorgyan, Arpine Dotti, Katia Fiorella Bajetta, Emilio Campiglio, Manuela Bianchi, Francesca Bregni, Giacomo Pietrantonio, Filippo |
author_facet | Martinetti, Antonia Miceli, Rosalba Sottotetti, Elisa Di Bartolomeo, Maria de Braud, Filippo Gevorgyan, Arpine Dotti, Katia Fiorella Bajetta, Emilio Campiglio, Manuela Bianchi, Francesca Bregni, Giacomo Pietrantonio, Filippo |
author_sort | Martinetti, Antonia |
collection | PubMed |
description | The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma samples from 50 patients treated at a single Institution were analysed using the multiplex assay BioPlex™ 2200 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA) at baseline, before first three cycles and subsequently every three cycles until disease progression. Prognostic analyses of baseline values were performed using multivariable Cox models, including disease extension >10 cm or ≤10 cm (measured as the sum of the diameters for all target lesions) as adjustment factor. The association between progression-free and overall survival and biomarkers modulation during treatment was studied using multivariable Cox models, which included summary statistics synthesizing during-treatment modulation together with disease extension. The biomarkers significantly associated with disease extension were baseline CEA (p = 0.012) and SDF-1 (p = 0.030). High values of VEGF and SDF-1 tended to be associated with worse prognosis, especially in terms of overall survival. The negative prognostic trend was more marked for baseline CEA as compared to other biomarkers; increasing values during treatment was significantly related to worse prognosis independently of disease extension (p = 0.007 and 0.016 for progression-free and overall survival, respectively). VEGF is related to bevacizumab pharmacodynamics and is associated to other angiogenic cytokines; some of the proposed biomarkers such as SDF-1 and CEA should be further validated for prognosis assessment and monitoring of bevacizumab-based treatment of advanced colorectal cancer. |
format | Online Article Text |
id | pubmed-4190566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-41905662014-10-09 Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens Martinetti, Antonia Miceli, Rosalba Sottotetti, Elisa Di Bartolomeo, Maria de Braud, Filippo Gevorgyan, Arpine Dotti, Katia Fiorella Bajetta, Emilio Campiglio, Manuela Bianchi, Francesca Bregni, Giacomo Pietrantonio, Filippo Cancers (Basel) Article The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. The aim of this study was to investigate the prognostic role of circulating VEGF, PDGF, SDF-1, osteopontin and CEA in patients randomly assigned to three bevacizumab-based regimens. Plasma samples from 50 patients treated at a single Institution were analysed using the multiplex assay BioPlex™ 2200 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA) at baseline, before first three cycles and subsequently every three cycles until disease progression. Prognostic analyses of baseline values were performed using multivariable Cox models, including disease extension >10 cm or ≤10 cm (measured as the sum of the diameters for all target lesions) as adjustment factor. The association between progression-free and overall survival and biomarkers modulation during treatment was studied using multivariable Cox models, which included summary statistics synthesizing during-treatment modulation together with disease extension. The biomarkers significantly associated with disease extension were baseline CEA (p = 0.012) and SDF-1 (p = 0.030). High values of VEGF and SDF-1 tended to be associated with worse prognosis, especially in terms of overall survival. The negative prognostic trend was more marked for baseline CEA as compared to other biomarkers; increasing values during treatment was significantly related to worse prognosis independently of disease extension (p = 0.007 and 0.016 for progression-free and overall survival, respectively). VEGF is related to bevacizumab pharmacodynamics and is associated to other angiogenic cytokines; some of the proposed biomarkers such as SDF-1 and CEA should be further validated for prognosis assessment and monitoring of bevacizumab-based treatment of advanced colorectal cancer. MDPI 2014-08-29 /pmc/articles/PMC4190566/ /pubmed/25256831 http://dx.doi.org/10.3390/cancers6031753 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Martinetti, Antonia Miceli, Rosalba Sottotetti, Elisa Di Bartolomeo, Maria de Braud, Filippo Gevorgyan, Arpine Dotti, Katia Fiorella Bajetta, Emilio Campiglio, Manuela Bianchi, Francesca Bregni, Giacomo Pietrantonio, Filippo Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens |
title | Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens |
title_full | Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens |
title_fullStr | Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens |
title_full_unstemmed | Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens |
title_short | Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens |
title_sort | circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190566/ https://www.ncbi.nlm.nih.gov/pubmed/25256831 http://dx.doi.org/10.3390/cancers6031753 |
work_keys_str_mv | AT martinettiantonia circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT micelirosalba circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT sottotettielisa circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT dibartolomeomaria circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT debraudfilippo circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT gevorgyanarpine circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT dottikatiafiorella circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT bajettaemilio circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT campigliomanuela circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT bianchifrancesca circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT bregnigiacomo circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens AT pietrantoniofilippo circulatingbiomarkersinadvancedcolorectalcancerpatientsrandomlyassignedtothreebevacizumabbasedregimens |